Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) said the grant of two US patents pushes its exclusivity over antibiotic iclaprim out to 2037.
It follows what’s called a notice of allowance for patents governing the drug’s use to treat bacterial infections, including acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis.
"These US patents provide additional exclusivity for iclaprim in the treatment of bacterial infections well into 2037,” said chief executive Graham Lumsden.
“We are actively building our intellectual property portfolio in the U.S. and other key markets around the globe."
Having successfully negotiated two Phase III clinical trials, Motif is gearing up to take its next-generation antibiotic to market.